New combo therapy aims to stop bile duct cancer return after surgery
NCT ID NCT07636824
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing whether giving chemotherapy (capecitabine or S-1) together with radiation after surgery can help prevent bile duct and gallbladder cancers from coming back. It includes 92 patients whose cancers had high-risk features, like positive lymph nodes or narrow surgical margins. The main goal is to see how many patients remain cancer-free two years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Capecitabine (or S-1) chemotherapy plus radiation therapy
- What this could lead to
- If successful, this could provide a standard treatment to reduce the chance of cancer returning after surgery for these aggressive cancers.
- What could go wrong
- This is a small, early-phase study (92 people) without a comparison group, so results may not be definitive. Chemoradiotherapy can cause significant side effects like fatigue, nausea, and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can matching drugs to tumor genes beat biliary cancer?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- Zapping spreading tumors could extend life on current cancer drugs
- Engineered immune cells take aim at two cancer targets in hard-to-treat bile duct cancers
- New drug duo takes on tough liver cancers